Neuronetics, Inc.
Neuronetics, Inc. (STIM) Financial Performance & Income Statement Overview
Review Neuronetics, Inc. (STIM) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Neuronetics, Inc. (STIM) Income Statement & Financial Overview
View the income breakdown for Neuronetics, Inc. STIM across both annual and quarterly reports.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $38.11M | $31.98M | $22.49M | $18.53M |
| Cost of Revenue | $20.35M | $16.24M | $7.60M | $4.53M |
| Gross Profit | $17.76M | $15.74M | $14.89M | $14.001M |
| Gross Profit Ratio | $0.47 | $0.49 | $0.66 | $0.76 |
| R&D Expenses | $1.80M | $1.62M | $5.77M | $2.42M |
| SG&A Expenses | $24.02M | $25.14M | $20.59M | $19.31M |
| Operating Expenses | $25.82M | $26.75M | $26.36M | $21.73M |
| Total Costs & Expenses | $46.17M | $42.99M | $33.96M | $26.26M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.97M | $1.92M | $1.76M | $1.73M |
| Depreciation & Amortization | $0.00 | $911000.00 | $446000.00 | $512000.00 |
| EBITDA | -$8.06M | -$9.86M | -$10.48M | -$11.10M |
| EBITDA Ratio | -$0.21 | -$0.31 | -$0.47 | -$0.60 |
| Operating Income | -$8.06M | -$11.01M | -$11.47M | -$7.73M |
| Operating Income Ratio | -$0.21 | -$0.34 | -$0.51 | -$0.42 |
| Other Income/Expenses (Net) | -$2.06M | -$1.68M | -$1.22M | -$5.61M |
| Income Before Tax | -$10.12M | -$12.69M | -$12.70M | -$13.34M |
| Income Before Tax Ratio | -$0.27 | -$0.40 | -$0.56 | -$0.72 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$10.12M | -$12.68M | -$12.16M | -$13.34M |
| Net Income Ratio | -$0.27 | -$0.40 | -$0.54 | -$0.72 |
| EPS | -$0.15 | -$0.21 | -$0.33 | -$0.44 |
| Diluted EPS | -$0.15 | -$0.21 | -$0.33 | -$0.44 |
| Weighted Avg Shares Outstanding | $66.18M | $61.47M | $36.67M | $30.27M |
| Weighted Avg Shares Outstanding (Diluted) | $66.18M | $61.47M | $36.67M | $30.27M |
Over the past four quarters, Neuronetics, Inc. demonstrated steady revenue growth, increasing from $18.53M in Q3 2024 to $38.11M in Q2 2025. Operating income reached -$8.06M in Q2 2025, maintaining a consistent -21% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$8.06M, reflecting operational efficiency. Net income rose to -$10.12M, with EPS at -$0.15. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan